Bicycle Therapeutics Reports Third Quarter 2026 Financial Results and Business Progress
Bicycle Therapeutics announced its financial results for the third quarter ended September 30, 2026, highlighting a narrowed net loss and the receipt of FDA Orphan Drug Designation for nuzefatide pevedotin.